Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 8/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105959 | 0.96 | ANPEP (0.40) | ANPEPLNPEPERAP2DPP7GNAI3 | |
| SCHEMBL3123566 | 0.86 | SIRT1 (0.33) | — | |
| SCHEMBL5501908 | 0.83 | NTRK1 (0.32) | — | |
| SCHEMBL3114440 | 0.83 | SIRT1 (0.37) | — | |
| SCHEMBL20540627 | 0.81 | NTRK1 (0.39) | — | |
| SCHEMBL3116047 | 0.79 | ANPEP (0.35) | ANPEPLNPEPERAP2 | |
| SCHEMBL5499871 | 0.78 | NTRK1 (0.33) | — | |
| SCHEMBL3118910 | 0.76 | NTRK1 (0.34) | — | |
| SCHEMBL3114392 | 0.75 | SIRT5 (0.42) | — | |
| SCHEMBL5497757 | 0.74 | BRD9 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| EP-1663245-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
| WO-2005027909-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | ANPEP 1812/4885LNPEP 2838/4885ERAP2 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.